American Society of Hematology

The Hematologist: ASH News and Reports, the Society's member newsletter, is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.

banner image

Designer Babies?

Dr. Hoggatt discusses implications of genomic engineering and suggests that attention, at the moment, focus on therapies in somatic cells to treat children and adults with genetic diseases.

Read more
banner image

The Unfiltered Truth

Dr. Garcia discusses a study that highlights the benefits of well-managed anticoagulation in patients with high risk pulmonary embolism.

Read more
banner image

Fresher Blood is Not Necessarily Better Blood

Drs. George and Lockhart look at the ABLE and RECESS trials to determine the extent to which RBC storage duration affects the blood supply used in transfusions. 

Read more
View All

Presidents Column

Dr_ David A_ Williams - Presidents Column

David A. Williams, MD

Chief of Hematology/Oncology; Director of Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts
ASH as a Global Organization
June 11, 2015

Dr. Williams discusses ASH's international presence through various programs and initiatives; he highlights the need for support for several changes in governance and membership structure to help ASH advance as a global organization.

View All

Clinical Trials Corner

Do We Need Another HDAC Inhibitor in Multiple Myeloma?
June 8, 2015

Dr. Raje and Dr. Yee discuss the need for new agents in the therapy or treatment of patients with multiple myeloma, taking into account the FDA approval of penobinostat, and a study that looks at HDAC inhibition.

View All

Ask The Hematologist

Ask the Hematologist: Treating Patients with Relapsed/Refractory Hairy Cell Leukemia
June 18, 2015

Dr. Kreitman talks about his management approaches to treating patients with relapsed or refractory hairy cell leukemia.

View All

Mini Review

Desialylated Platelets: A Missing Link in Hepatic Thrombopoietin Regulation
April 14, 2015

Drs. Falet, Grozovsky, and Hoffmeister look at desialylated platelets to understand the steady state of hepatic TPO regulation and the mechanisms of thrombocytopenia observed in patients with MPNs treated with JAK1/2 inhibitors.

View All

Op Ed

Is the NIH Expert Report on Sickle Cell Disease a “Clinical Practice Guideline We Can Trust?”
November 19, 2014

Dr. Alexis Thompson makes a thorough assessment of the latest clinical practice guidelines for sickle cell disease.

View All
  • A Report from the AMA House of Delegates

    In the first weekend of June in Chicago, representatives from medical specialty societies and state medical societies convened a meeting of the semi-annual American Medical Association (AMA) House of Delegates.  The House of Delegates is composed of more than 500 physician representatives, and they consider resolutions covering a wide gamut of issues, such as health information technology, maintenance of certification, and menu labeling for food allergies.  ASH was represented at the meeting this year.  Follow the link to read more.

  • ASH Supports Request by ASBMT and NMDP to Expand Medicare Coverage for Stem Cell Transplant

    In online comments submitted to CMS, ASH strongly supported expanding the coverage indications for the use of hematopoietic stem cell transplant for patients covered by Medicare. Under the current coverage determination, some conditions, such as myelodysplastic syndromes, are covered under a policy called Coverage with Evidence Development (CED), which allows for Medicare coverage in exchange for the provision of certain clinical data. The request that ASH supported aims to move three conditions from the category of not being named at all into the category of being covered nationwide - sickle cell disease, myelofibrosis, and lymphoma.  Follow the link above to learn more.

  • NIH Seeks Information on Optimizing Funding Policies and Other Strategies to Improve the Impact and Sustainability of Biomedical Research

    The NIH has released a request for information soliciting input on the possible development of new policies and strategies to improve the impact and sustainability of its funded biomedical research enterprise.  ASH members are encouraged to submit comments in response to this request.

  • CMS Issues Guidance on Biosimilar Reimbursement and Formulary Policy

    On March 30, the Centers for Medicare & Medicaid Services (CMS) issued two documents on Medicare Part B and Part D payment for biosimilars that are relevant to hematology.  On March 6, 2015, the FDA)approved filgrastim-sndz (ZARXIO Injection, Sandoz Inc.), as a biosimilar to U.S.-licensed Neupogen, which is important to hematologic therapy.  Some of the most important regimens for the treatment of patients with hematologic disorders are biologic, so the release of this information is helpful for the field.

View all policy news
back to top